[Hinews] AUSTIN, Texas — OrganoidScience, a South Korean biotechnology firm, announced on July 25, 2025, the establishment of its U.S. subsidiary, Organoids by Southwest, in Texas on July 22, signaling a bold move to expand its footprint in the American market. Breaking from the biotech industry’s preference for Boston or Silicon Valley, the company has chosen Austin and Houston as strategic hubs, while its Boston office continues to focus on partnerships with East Coast pharmaceutical companies and hospitals.

The Texas subsidiary will prioritize the integration of healthcare technology and the commercialization of organoid-based therapies.

Strategic Bases in Austin and Houston

Austin, a thriving hub for technology giants like Dell Technologies, Samsung Electronics, Apple, and Tesla, is also gaining prominence in biotechnology and healthcare. OrganoidScience is capitalizing on this ecosystem through a collaboration with the University of Texas at Austin’s Dell Medical School and its affiliated hospital to advance research on rare and intractable diseases. The company has engaged in discussions with UT Austin professors Audrey Brumback and Ankit Sabharwal for joint research initiatives and is exploring partnerships with robotics and mechanical engineering faculty to develop automation and organ-on-chip technologies.

Photo: OrganoidScience provided imagery related to the Texas subsidiary launch.
Photo: OrganoidScience provided imagery related to the Texas subsidiary launch.

OrganoidScience has secured a presence at UT Austin’s Innovation Center, where it will establish a research facility and strengthen academic-industry collaborations.

In Houston, home to the world-renowned Texas Medical Center (TMC), the company aims to lead in regenerative therapeutics and precision medicine commercialization. It is partnering with institutions such as MD Anderson Cancer Center and Texas Children’s Hospital to expand the indications for its inflammatory bowel disease therapy, ATORM-C.

Advancing Clinical Development

The company is also deepening its collaboration with Mount Sinai Hospital in New York, leveraging its leading inflammatory bowel disease program to accelerate U.S. clinical trials for ATORM-C.

Leadership Vision

Kyung-Jin Lee, OrganoidScience’s chief technology officer, who oversaw the Texas subsidiary’s launch, underscored the region’s strategic value. “By partnering with Texas’s premier technology and medical infrastructure, we aim to enhance our global competitiveness,” Lee said.

A Platform for Growth

The Texas subsidiary positions OrganoidScience to scale its organoid technology across the United States, solidifying its ambition to become a leading biotech platform company. This expansion marks a significant step toward global leadership in organoid-based therapeutics and precision medicine.

키워드

#오가노이드사이언스
저작권자 © Hinews 무단전재 및 재배포 금지
ad